Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Piramanayagam, Arunachalam"'
Autor:
Mani, Shobana1 shob957@gmail.com, Piramanayagam, Arunachalam1, Kalavakolanu, Sharada Sivaram2
Publikováno v:
Journal of Pharmaceutical Negative Results. 2022 Special Issue, Vol. 13, p298-305. 8p.
Publikováno v:
Journal of Pharmaceutical Negative Results; 2022 Special Issue, Vol. 13, p306-311, 6p
Autor:
Kathiravan Asokan, Piramanayagam Arunachalam, Mahammed Kaspady, Lakshmikant Bajpai, Dauh-Rurng Wu, Ramakanth Sarabu, Harshavardhan Naidu, Khaja Mohiddin Shaik, Arvind Mathur
Publikováno v:
Journal of chromatography. A. 1511
Purification of many pharmaceutical compounds by supercritical fluid chromatography (SFC) has always been challenging because of degradation of compound during the isolation step in the presence of acidic or basic modifiers in the mobile phase. Stabi
Autor:
Hai-Yun, Xiao, Scott H, Watterson, Charles M, Langevine, Anurag S, Srivastava, Soo S, Ko, Yanlei, Zhang, Robert J, Cherney, Wei-Wei, Guo, John L, Gilmore, James E, Sheppeck, Dauh-Rurng, Wu, Peng, Li, Duraisamy, Ramasamy, Piramanayagam, Arunachalam, Arvind, Mathur, Tracy L, Taylor, David J, Shuster, Kim W, McIntyre, Ding-Ren, Shen, Melissa, Yarde, Mary Ellen, Cvijic, Anthony M, Marino, Praveen V, Balimane, Zheng, Yang, Dana M, Banas, Georgia, Cornelius, Celia J, D'Arienzo, Bethanne M, Warrack, Lois, Lehman-McKeeman, Luisa M, Salter-Cid, Jenny, Xie, Joel C, Barrish, Percy H, Carter, Alaric J, Dyckman, T G Murali, Dhar
Publikováno v:
Journal of medicinal chemistry. 59(21)
Fingolimod (1) is the first approved oral therapy for the treatment of relapsing remitting multiple sclerosis. While the phosphorylated metabolite of fingolimod was found to be a nonselective S1P receptor agonist, agonism specifically of S1P